FAS Wealth Partners Inc. Grows Stock Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

FAS Wealth Partners Inc. grew its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 134.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,429 shares of the exchange traded fund’s stock after purchasing an additional 2,540 shares during the quarter. FAS Wealth Partners Inc.’s holdings in SPDR S&P Biotech ETF were worth $395,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. increased its position in shares of SPDR S&P Biotech ETF by 179.1% during the 1st quarter. JPMorgan Chase & Co. now owns 7,534,471 shares of the exchange traded fund’s stock valued at $574,202,000 after purchasing an additional 4,835,071 shares during the last quarter. Phoenix Holdings Ltd. increased its holdings in SPDR S&P Biotech ETF by 0.8% in the 3rd quarter. Phoenix Holdings Ltd. now owns 2,151,359 shares of the exchange traded fund’s stock worth $157,092,000 after acquiring an additional 17,221 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in SPDR S&P Biotech ETF by 103.3% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,771,000 shares of the exchange traded fund’s stock worth $129,318,000 after acquiring an additional 900,000 shares in the last quarter. Jane Street Group LLC increased its holdings in SPDR S&P Biotech ETF by 315.1% in the 1st quarter. Jane Street Group LLC now owns 1,529,813 shares of the exchange traded fund’s stock worth $116,587,000 after acquiring an additional 1,161,234 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in SPDR S&P Biotech ETF in the 3rd quarter worth approximately $102,900,000.

SPDR S&P Biotech ETF Trading Down 3.4 %

SPDR S&P Biotech ETF stock opened at $90.68 on Wednesday. The firm has a 50 day moving average of $93.71 and a 200 day moving average of $83.03. The firm has a market capitalization of $6.96 billion, a price-to-earnings ratio of 11.47 and a beta of 0.97. SPDR S&P Biotech ETF has a 12-month low of $63.80 and a 12-month high of $103.52.

SPDR S&P Biotech ETF Company Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Read More

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.